|Number of pages||2|
|Publication status||Published (in print/issue) - 23 Jan 2021|
Bibliographical noteFunding Information:
CWlR declares grant funding from Science Foundation Ireland (12/YI/B2480), the Health Research Board (USIRL-2016-2), and the Irish Research Council (IRCLA/2017/234) in the area of type 2 diabetes. CWlR serves on advisory boards for Novo Nordisk, Herbalife, Boehringer Ingelheim, Johnson & Johnson, Keyron, AnaBio, and Sanofi, outside of the area of work commented on here. ADM declares no competing interests.
- Bariatric Surgery
- Diabetes Mellitus, Type 2/drug therapy
- Follow-Up Studies
- Glycated Hemoglobin A/analysis